about
Normal Non-HDL Cholesterol, Low Total Cholesterol, and HDL Cholesterol Levels in Sickle Cell Disease Patients in the Steady State: A Case-Control Study of Tema Metropolis.Exploring the C-terminal tail dynamics: Structural and molecular perspectives into the therapeutic activities of novel CRMP-2 inhibitors, Naringenin and Naringenin-7-O- glucuronide, in the treatment of Alzheimer's diseaseCovalent simulations of covalent/irreversible enzyme inhibition in drug discovery: a reliable technical protocolMicrobes, not humans: exploring the molecular basis of Pseudouridimycin selectivity towards bacterial and not human RNA polymeraseAn update on the discovery and development of selective heat shock protein inhibitors as anti-cancer therapyCo-inhibition as a strategic therapeutic approach to overcome rifampin resistance in tuberculosis therapy: atomistic insightsCovalent Inhibition in Drug Discovery: Filling the Void in LiteratureProbing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 ProteinsSynergistic Interplay of The Co-administration of Rifampin And Newly Developed Anti-TB Drug: Could It Be a Promising New Line of TB Therapy?The irony of chirality - unveiling the distinct mechanistic binding and activities of 1-(3-(4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)pyrrolidin-1-yl)prop-2-en-1-one enantiomers as irreversible covalent FGFRHuman Rhinovirus Inhibition Through Capsid "Canyon" Perturbation: Structural Insights into The Role of a Novel Benzothiophene DerivativeA dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapyAn Update on the Pharmacological Usage of Curcumin: Has it Failed in the Drug Discovery Pipeline?
P50
Q40452222-BCBAFF5D-2EF6-490F-A700-11C3A94C5F8CQ56979095-EDA8AF86-8988-4BF1-B2E2-FFBF5CA56669Q57055258-9845D4DF-2873-4575-AC07-4CDDDBE5DABFQ58093259-064F969F-6D93-4145-8F2E-072BEBFEDBDAQ60218239-5E52F3EF-12AA-49E9-980A-75B903C9FC8CQ60218246-B6210FE4-85CE-42B0-A01B-086FBF28FB97Q60218251-C4A82015-65A2-493B-B42D-920DEF1FB564Q60218273-8AA9E7D4-A04C-4923-8AA1-A746565A6F24Q60218281-4371BBBC-E68A-49F0-8290-699DA036267BQ91052321-6A2615B2-0A4E-44E3-8F64-DDC33F592423Q91956590-3A10AC58-EB51-4421-B00D-5ABFEF6BEA5AQ93087342-79FCAFE5-1353-4CDB-AE05-4EF8858D215AQ96173281-3F87E319-1CF8-4421-9285-566D9FBA5D60
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Clement Agoni
@ast
Clement Agoni
@en
Clement Agoni
@es
Clement Agoni
@nl
type
label
Clement Agoni
@ast
Clement Agoni
@en
Clement Agoni
@es
Clement Agoni
@nl
prefLabel
Clement Agoni
@ast
Clement Agoni
@en
Clement Agoni
@es
Clement Agoni
@nl
P1153
57203156494
P31
P496
0000-0001-6130-8031